Skip to content

Influence of deep brain stimulation in the pedunculopontine nuclei on therapy-resistant gait and balance disorders in patients with idiopathic and atypical parkinsonian syndromes

Influence of deep brain stimulation in the pedunculopontine nuclei on therapy-resistant gait and balance disorders in patients with idiopathic and atypical parkinsonian syndromes

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
DRKS
Registry ID
DRKS00012596
Enrollment
20
Registered
2017-11-07
Start date
2009-06-23
Completion date
Unknown
Last updated
2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

G20.9 G23.1

Interventions

Group 1: 1. Screening and basic investigations - Patient Information and consent - Evaluation of the inclusion / exclusion criteria - Collection of demographic data, including medical history and medi

Sponsors

Universitätsklinik für Stereotaktische Neurochirurgie
Lead Sponsor

Eligibility

Sex/Gender
All
Age
40 Years to 75 Years

Inclusion criteria

Inclusion criteria: - Diagnosis of a probable PSP (Parkinsonsyndrom, progressive disease after the age of 40, PSP and marked postural instability with falls after the first year of the disease) - UPDRS- item 13> / = 2 (2 = occasional falls, less than once a day) or PSPRS- item 5> / = 2 (average frequency of falls when walking without support, 2 = 1-4 falls per month) - UPDRS- item 30> / = 2 (posture stability, 2 = response to a sudden backward-Pulling on the shoulders, while the patient stands with open eyes and legs slightly apart. The patient is prepared for it: no compensatory movement, would fall if not caught by the examiner) or PSPRS- Item 27> / = 2 (postural stability, patient would fall if not caught by the examiner)

Exclusion criteria

Exclusion criteria: - Dementia (Mattis Dementia Rating Scale Score <130/144) - pronounced cerebral atrophy or pronounced brain parenchyma damage - coagulation disorders (eg oral anticoagulation therapy, hepatic dysfunction) - Reduced immune defense (immunosuppressive therapy or immune disease) - other internal concomitant disease with significantly increased risk of operation - Malignant disease - Known epilepsy - severe psychiatric illness (psychosis, severe depression, severe personality disorder).

Design outcomes

Primary

MeasureTime frame
Evaluation of the effectiveness of DBS (Deep Brain Stimulation) in the area of the PPN (pedunculopotines nuclei) in patients with the diagnosis of PSP (Progressive Supranuclear Palsy) on the basis of clinical and apparative changes of the motor scales by the THS in the PPN in the long-term course up to 24 months

Secondary

MeasureTime frame
- Evaluation of optimal target point determination for implantation of electrodes for DBS (Deep Brain Stimulation) into the PPN (pedunculopotines nuclei) - Evaluation of the safety and tolerability of the implantation of electrodes for deep brain stimulation into the PPN

Countries

Germany

Contacts

Public ContactImke Galazky

Universitätsklinik für Stereotaktische Neurochirurgie

imke.galazky@med.ovgu.de+49-391-67-21667

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026